Mayo Clinic Hospital

Running trials

• Not yet recruiting

  A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

  NCT07604285· Phase 1/2· Myosin Therapeutics Inc.· Source

• Recruiting

  A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

  NCT07185880· Phase 1/2· Myosin Therapeutics Inc.· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  NCT07216027· Phase 2· Pfizer· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· Phase 1· Incyte Corporation· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

  NCT06641466· Phase 3· Pfizer· Source

• Recruiting

  Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  NCT06772623· Phase 1/2· AbbVie· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Recruiting

  A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  NCT06706076· Phase 1/2· BlossomHill Therapeutics· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  NCT06690775· Phase 2· TORL Biotherapeutics, LLC· Source

• Recruiting

  A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  NCT06369285· Phase 2· Puma Biotechnology, Inc.· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

  NCT06644768· Phase 1/2· Daiichi Sankyo· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

  NCT06388564· Phase 2· Incyte Corporation· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

  NCT06445062· Phase 1/2· Revolution Medicines, Inc.· Source

• Active, not recruiting

  Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06158841· Phase 3· AbbVie· Source

• Recruiting

  A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  NCT06179160· Phase 1· Incyte Corporation· Source

• Recruiting

  A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  NCT06131840· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· PharmaMar· Source

• Recruiting

  A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  NCT05895786· Phase 3· Pfizer· Source

• Active, not recruiting

  STOP-HER2: Stopping Trastuzumab in HER2+ MBC

  NCT05721248· Phase 2· Dana-Farber Cancer Institute· Source

• Active, not recruiting

  A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

  NCT05794906· Phase 3· Bayer· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

  NCT05217446· Phase 2· Pfizer· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

  NCT04910022· Phase 1/2· Nerviano Medical Sciences· Source

• Recruiting

  CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  NCT05143996· Phase 1/2· Cullinan Therapeutics Inc.· Source

• Recruiting

  Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  NCT04981119· A2 Biotherapeutics Inc.· Source

• Active, not recruiting

  A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

  NCT04965493· Phase 3· Loxo Oncology, Inc.· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Pfizer· Source

• Active, not recruiting

  CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

  NCT04495153· Phase 2· Candel Therapeutics, Inc.· Source

• Active, not recruiting

  Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

  NCT04430738· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

  NCT04416984· Phase 1/2· Allogene Therapeutics· Source

• Active, not recruiting

  Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

  NCT03915184· Phase 1/2· CARsgen Therapeutics Co., Ltd.· Source

• Recruiting

  Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

  NCT03567889· Phase 3· Philogen S.p.A.· Source

• Active, not recruiting

  DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

  NCT03115333· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  NCT03165734· Phase 3· Swedish Orphan Biovitrum· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer6 recruiting
• Glioblastoma6 recruiting
• Pancreatic cancer6 recruiting
• Lung cancer4 recruiting
• Gastric and oesophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Ovarian cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  NCT05580588· Phase 2· Shanghai Pharma Biotherapeutics USA Inc.· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Completed

  A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

  NCT05143957· Phase 2· Ionis Pharmaceuticals, Inc.· Source

• Completed

  XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT05005728· Phase 2· Xencor, Inc.· Source

• Completed

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  NCT05014412· Phase 2· Pfizer· Source

• Completed

  UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

  NCT04382664· Phase 2· Ultimovacs ASA· Source

• Completed

  Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care

  NCT04000971· Vanderbilt University Medical Center· Source

• Completed

  Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979· Phase 3· Washington University School of Medicine· Source

• Completed

  Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

  NCT04057040· Phase 2· Protagonist Therapeutics, Inc.· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Kite, A Gilead Company· Source

• Completed

  Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

  NCT02873195· Phase 2· Academic and Community Cancer Research United· Source

• Completed

  Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

  NCT03037385· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

  NCT00309985· Phase 3· ECOG-ACRIN Cancer Research Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation76 works · 0 trials
• Prostate cancer49 works · 3 trials
• Multiple myeloma34 works · 4 trials
• Pancreatic cancer28 works · 6 trials
• Migraine22 works · 1 trial
• Ventricular tachycardia21 works · 0 trials
• Neuroendocrine tumours18 works · 2 trials
• Amyloidosis17 works · 0 trials
• Head and neck cancer16 works · 2 trials
• Aortic stenosis15 works · 0 trials
• Hypertrophic cardiomyopathy15 works · 0 trials
• Mantle cell lymphoma15 works · 0 trials
• Myeloproliferative neoplasms12 works · 4 trials
• Aortic aneurysm11 works · 0 trials
• Dilated cardiomyopathy8 works · 0 trials
• Chronic lymphocytic leukaemia7 works · 2 trials
• Follicular lymphoma6 works · 0 trials